Compare AIHS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIHS | TOVX |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.4M |
| IPO Year | 2017 | 2012 |
| Metric | AIHS | TOVX |
|---|---|---|
| Price | $1.75 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.0K | ★ 8.5M |
| Earning Date | 02-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.63 | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,389,072.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.16 |
| 52 Week High | $8.26 | $1.50 |
| Indicator | AIHS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 72.72 | 63.36 |
| Support Level | $1.84 | $0.17 |
| Resistance Level | $3.07 | $0.26 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 67.55 | 44.68 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.